LifeCell snared in $1.7B buyout deal

Kinetic Concepts has inked a deal to buy LifeCell for $1.7 billion, a cash transaction that applies an 18 percent premium to the maker of tissue-based products. In the deal, LifeCell becomes a biosurgery division of Kinetic Concepts. LifeCell will remain in Branchburg, NJ.

"This combination allows us to accelerate our strategy to increase Kinetic's presence in the operating room and will leverage our broad global market reach to drive future growth of LifeCell's products," said Kinetic CEO Catherine Burzik in a statement.

- see the release
- read the AP report

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.